Technical Data
V2110-15T
Vascular Endothelial Growth Factor, Recombinant, Human (VEGF, Vascular Endothelial Growth Factor A, VEGFA, VEGF-A, MGC70609, MVCD1, Vascular Permeability Factor, VPF)
2ug
Growth Factors, Cytokines Storage: -20CShipping: Blue Ice
Source:
Recombinant corresponding to 165aa of human Vascular Endothelial Growth Factor expressed in E.coli is a double, non-glycosylated, polypeptide chain.

Molecular Weight:
~38.2kD

Biological Activity:
The biological activity is determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1.0-8.0 nug/ml.

Dimers and Aggregates:
1% (SDS-PAGE)

Protein Content:
Protein quantitation was carried out by two independent methods:1. UV spectroscopy at 280nm using the absorbency value of 0.2875 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of VEGF as a Reference Standard.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Molecular Weight:
~38.2kD
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug)
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. VEGF as a therapeutic target in cancer. Oncology 2005;69 Suppl 3:11-6. 2. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10. 3. Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. Oncology 2005;69 Suppl 3:1-3. 4. Biological effects of a software-controlled voltage pulse generator (PhyBack PBK-2C) on the release of vascular endothelial growth factor (VEGF). In Vivo 2005 Nov-Dec;19(6):949-58. 5. Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res 2005 Oct 20; 33(18):6070-80. 6. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005 Oct;8(4):299-309.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.